King Pharmaceuticals news from FierceBiotech
NewsPalatin slashes staff, dumps research program
Palatin Technologies is cutting about a third of its workforce and dumping one of its lead development programs--an effort to find a better tolerated successor to sildenafil. After studying research Read more...
ALSO NOTED: Solvay drug 'approvable'; ChemGenex touts trial results: Asuragen raises $18.5M in venture cash; and much more...
> FDA staffers say that Solvay's experimental therapy for atrial fibrillation is approvable--with conditions. Report > Shares of Read more...
Remoxy meets Phase III endpoint for pain
Pain Therapeutics and King Pharmaceuticals have announced positive results of a Phase III study of Remoxy for patients with chronic participated pain. Remoxy is an abuse-deterrent version of Read more...
SPOTLIGHT: King asks FDA to block ZymoGenetics' drug
King Pharmaceuticals has petitioned the FDA not to approved ZymoGenetics' rThrombin, a treatment Read more...
King, Acura ink drug abuse technology deal
King Pharmaceuticals is paying Acura Pharmaceuticals $30 million up front for licensing rights to Acura's technology for preventing drug abuse. The North American pact will support King's work Read more...
King cuts 20% of workforce
Tennessee-based King Pharmaceuticals said it will cut its workforce by 20 percent due to problems the company is having with its Altace franchise. Last month King Pharmaceuticals lost its fight with Read more...
Palatin slashes staff following FDA objections
With its lead therapy raising some serious safety concerns at the FDA, Palatin Technologies Read more...
King bails on Palatin's FSM program
Less than two weeks after U.S. drug regulators raised serious doubts about the safety of bremelanotide for ED, King Read more...
Safety concerns force delay for Phase III ED trial
With regulators at the FDA waving a red flag over safety concerns, King Pharmaceuticals and Palatin Technologies announced that they will delay the planned launch of a Phase III trial of Read more...
ALSO NOTED: NicOx gains $5M from Merck; King sells manufacturing facility; and much more...
> Merck has begun clinical trials to develop nitric oxide-donating antihypertensive agents, triggering a €5 million milestone payment to NicOx. Read more...
| Press ReleasesPRESS RELEASE: King Pharmaceutical in Pact with Acura Pharmaceuticals to Develop Painkillers King Pharmaceutical in Pact with Acura Pharmaceuticals to Develop Painkillers BRISTOL, Tenn. and PALATINE, Ill., Oct. 31 -- King Pharmaceuticals, Inc. and Acura Pharmaceuticals, Inc. announced today Read more... PRESS RELEASE: King Pharmaceuticals to Cut Costs, 20 Percent of Work Force King Pharmaceuticals to Cut Costs, 20 Percent of Work Force BRISTOL, Tenn. -- King Pharmaceuticals announced today actions it is taking to accelerate a planned strategic shift, emphasizing its focus Read more... PRESS RELEASE: King Pharmaceuticals Reports Plan To File A Motion For Rehearing And Rehearing En Banc King Pharmaceuticals Reports Plan To File A Motion For Rehearing And Rehearing En Banc BRISTOL, TN, September 12, 2007 – King Pharmaceuticals reported today that the Company plans to file a motion Read more... PRESS RELEASE: Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program CRANBURY, N.J. – September 10, 2007--Palatin Technologies today announced it has reacquired full rights to Read more... PRESS RELEASE: King, Palatin Immediate Plans for Phase 3 Clinical Program King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction CRANBURY, N.J. and BRISTOL, Tenn., Aug. 30 -- Palatin Read more... |
Get more King Pharmaceuticals coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets